{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:32:26Z","timestamp":1790573546798,"version":"4.1.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Comprehensive genomic profiling (CGP) has expanded treatment options for metastatic castration-resistant prostate cancer (mCRPC); however, real-world data on its clinical utility in Japanese patients remain limited. To address this gap, we conducted a multicenter real-world analysis to evaluate the implementation and clinical relevance of CGP in Japanese patients with mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 128 patients with mCRPC who underwent CGP at four Japanese institutions using FoundationOne\u00ae CDx, FoundationOne\u00ae Liquid CDx, or OncoGuide\u2122 NCC Oncopanel. We assessed the prevalence of druggable genomic signatures, including BRCA pathogenic variants (PVs), microsatellite instability-high (MSI-high), and tumor mutational burden-high (TMB-high), and described subsequent use of genomically matched therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age at CGP testing was 73\u00a0years, and patients had received a median of three prior systemic treatment lines. BRCA PVs were identified in 18 patients (14%), MSI-high in 4 (3%), and TMB-high in 11 (9%); all MSI-high cases were also TMB-high. Overall, 26 patients (20%) harbored either BRCA PVs or TMB-high status. Among these, 14 patients (54%) received matched targeted therapies, including poly(ADP-ribose) polymerase inhibitors or pembrolizumab. BRCA PVs were detected in 17% of tissue-based (F1 CDx) assays and 9% of liquid-based assays, without a statistically significant difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CGP identified BRCA PVs, MSI-high, or TMB-high in 20% of patients with metastatic CRPC, supporting its value in guiding precision oncology. However, only some patients received matched therapy, supporting earlier CGP testing. Routine integration of CGP may facilitate precision oncology-guided treatment decision-making in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag039","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:26:02Z","timestamp":1771849562000},"page":"879-884","source":"Crossref","is-referenced-by-count":1,"title":["Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8957-0429","authenticated-orcid":false,"given":"Yosuke","family":"Yasuda","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45, Yushima, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45, Yushima, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1629-7171","authenticated-orcid":false,"given":"Sadakatsu","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Precision Cancer Medicine, Institute of Science Tokyo , 1-5-45, Yushima, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2607-1013","authenticated-orcid":false,"given":"Ichiro","family":"Yonese","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , 3-18-22 Honkomagome, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Urology, Saitama Cancer Center , 780 Oojikomuro, Inacho, Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Urasaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Saitama Cancer Center , 780 Oojikomuro, Inacho, Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45, Yushima, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , 3-18-22 Honkomagome, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-628X","authenticated-orcid":false,"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[{"name":"Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Urology, Saitama Cancer Center , 780 Oojikomuro, Inacho, Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , 3-18-22 Honkomagome, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[{"name":"Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Science Tokyo , 1-5-45, Yushima, Bunkyo-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026070605420869700_ref1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"2026070605420869700_ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026070605420869700_ref3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"2026070605420869700_ref4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026070605420869700_ref5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"2026070605420869700_ref6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070605420869700_ref7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet (London, England)"},{"key":"2026070605420869700_ref8","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/iju.15261","article-title":"Efficacy and safety profile of olaparib for patients with metastatic castration-resistant prostate cancer: a preliminary report of real-world data in a single institution in Japan","volume":"30","author":"Yasuda","year":"2023","journal-title":"Int J Urol"},{"key":"2026070605420869700_ref9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/jjco\/hyad185","article-title":"Prevalence of germline BRCA1\/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice","volume":"54","author":"Maekawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026070605420869700_ref10","doi-asserted-by":"publisher","first-page":"e77300","DOI":"10.7759\/cureus.77300","article-title":"Comprehensive genome profiling test in Japanese patients with castration-resistant prostate cancer: a single-Center retrospective study","volume":"17","author":"Hori","year":"2025","journal-title":"Cureus"},{"key":"2026070605420869700_ref11","volume-title":"FDA Grants Accelerated Approval to Pembrolizumab for First Tissue\/Site Agnostic Indication","author":"Administration USFaD","year":"2017"},{"key":"2026070605420869700_ref12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070605420869700_ref13","doi-asserted-by":"publisher","first-page":"e225394","DOI":"10.1001\/jamanetworkopen.2022.5394","article-title":"Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer","volume":"5","author":"Graf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026070605420869700_ref14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026070605420869700_ref15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026070605420869700_ref16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070605420869700_ref17","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070605420869700_ref18","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026070605420869700_ref19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026070605420869700_ref20","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med"},{"key":"2026070605420869700_ref21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s44276-024-00049-7","article-title":"Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project","volume":"2","author":"Shiota","year":"2024","journal-title":"BJC Rep"},{"key":"2026070605420869700_ref22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026070605420869700_ref23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/pros.24926","article-title":"Comprehensive genomic profiling testing for castration-resistant prostate cancer in advanced elderly patients: a single-Center retrospective cohort study","volume":"85","author":"Fukushima","year":"2025","journal-title":"Prostate"},{"key":"2026070605420869700_ref24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/jjco\/hyae003","article-title":"Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer","volume":"54","author":"Koguchi","year":"2024","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/879\/67318527\/hyag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/7\/879\/67318527\/hyag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:42:19Z","timestamp":1783330939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/7\/879\/8516626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag039","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,3,12]]}}}